On 30 October 2025, Joinn Laboratories (China) Co., Ltd. (stock code: 6127) released an announcement regarding the expiration of its fourth board session and the proposed election of the fifth session. The current executive directors—namely, Ms. Feng Yuxia (Chairperson), Ms. Sun Yunxia, Mr. Gao Dapeng, Mr. Gu Jingliang, and Ms. Luo Xi—together with the independent non-executive directors Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan, and Mr. Ying Fangtian, intend to stand for re-election at the Company’s second extraordinary general meeting of 2025.
According to the announcement, each of the nominees has confirmed that there are no other matters requiring shareholders’ attention under the Listing Rules, aside from information disclosed in the biographies appended to the document. Upon approval during the extraordinary general meeting, each re-elected director is expected to serve a three-year term and enter into a service contract with the Company for that duration, with remuneration details to be disclosed in its annual report.
The announcement highlights the directors’ backgrounds and shareholding details. It notes that the Chairperson, Ms. Feng, holds 167,160,633 A shares, while her spouse holds 74,725,981 A shares. Ms. Sun holds 2,678,907 A shares, Mr. Gao holds 282,746 A shares, and Mr. Gu holds 203,292 A shares. The newly appointed executive director, Ms. Luo, joined the Company following experience in global investment banking and financial management roles.
Brief biographical information is provided for each nominee. Ms. Feng, skilled in medicine and pharmacology, has served as a founder and leader of the Company since 1995. Ms. Sun has more than two decades of experience in drug safety evaluation. Mr. Gao, holding a background in finance, serves as general manager and oversees operations, capital management, and information disclosure. Mr. Gu focuses on pharmacodynamics, toxicology, and brand management, while Ms. Luo’s expertise covers capital market transactions and corporate finance.
The independent non-executive directors also bring expertise from various sectors, including banking, investment, securities, and scientific research. Mr. Zhang specializes in financial services and capital market transactions for Chinese financial institutions. Mr. Yang Changyun has held managerial positions in securities and asset management, and he has served as an independent director of the Company since early 2025. Mr. Yang Fuquan is a researcher in analytical chemistry, affiliated with prominent institutions and academic committees. Mr. Ying, an academician of the European Academy of Engineering, contributes experience in industrial design and engineering innovation.
Each candidate has stated that there is no additional information to disclose concerning their nominations, other than what is provided in the announcement. The election outcome will be determined at the second extraordinary general meeting of 2025, and the Company’s shareholders will decide on the formation of the fifth session of the Board at that time.
Comments